Loading…
ABVC BioPharma, Inc. is projected to rise to $1.17 by 2027, a +12% move from its current price of $1.04. ABVC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.9868 | $1.04 | $1.10 | +0.03% |
| Aug 6 | $0.9657 | $1.04 | $1.12 | +0.06% |
| Aug 7 | $0.9499 | $1.04 | $1.14 | +0.09% |
| Aug 8 | $0.9368 | $1.04 | $1.16 | +0.12% |
| Aug 9 | $0.9255 | $1.04 | $1.17 | +0.15% |
| Aug 10 | $0.9154 | $1.04 | $1.19 | +0.18% |
| Aug 11 | $0.9062 | $1.04 | $1.20 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9062 | $1.04 | $1.20 | +0.21% |
| Week 2 | $0.857 | $1.04 | $1.27 | +0.41% |
| Week 3 | $0.8214 | $1.05 | $1.33 | +0.62% |
| Week 4 | $0.7928 | $1.05 | $1.39 | +0.82% |
| Week 5 | $0.7687 | $1.05 | $1.44 | +1.03% |
| Week 6 | $0.7476 | $1.05 | $1.48 | +1.24% |
| Week 7 | $0.7289 | $1.06 | $1.53 | +1.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is based in Fremont, California and is advancing a diverse pipeline across oncology, neurology and ophthalmology with several ABV programs in Phase II or Phase I/II trials.
This includes ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.
ABVC BioPharma, Inc. currently trades at $1.02 per share with a market cap of $26.52M and is ranked 4599. Its category is Healthcare. The stock sits within a small-cap market position and faces near-term price dynamics that are reflected in a 30-day technical picture described below.
The price outlook from the forecast shows a path to higher prices over time, with 2030 and beyond delivering bullish prospects. The forecast for 2026–2028 is neutral to mildly positive, with notable upside appearing from 2030 onward, including a 2030 average of $1.38 and a 2050 maximum of $16.06. The near term includes a year (2029) with a negative ROI example, illustrating the inherent volatility in this small-cap forecast.
A major floor 67.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.9% away) — a key level to hold.
The nearest ceiling, 94.2% above — a clean break opens room to run.
A major ceiling 126.6% above — clearing it would confirm fresh momentum.
Key ABVC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABVC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.04 | Buy | $1.06 | Sell |
| MA 10 | $1.11 | Sell | $1.12 | Sell |
| MA 20 | $1.32 | Sell | $1.23 | Sell |
| MA 50 | $1.35 | Sell | $1.30 | Sell |
| MA 100 | $1.27 | Sell | $1.39 | Sell |
| MA 200 | $1.76 | Sell | $1.58 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.24 | Neutral |
| Stoch RSI (14) | 26.64 | Neutral |
| CCI (20) | -89.87 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -21.09 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.74 | Sell |
| Awesome (5,34) | -0.33 | Sell |
| Ultimate (7,14,28) | 31.16 | Neutral |
| Momentum (10) | -0.24 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 1.00 | Buy |
| ADX (14) | 24.68 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is BEARISH. The RSI(14) is 30, and the stock trades around the SMA50 of $1.35 as well as below the SMA200 of $1.81. The established near-term support is at $1.02 and resistance at $2.02.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.909 | $1.04 | $1.41 | 0% | Neutral | |
| $0.8518 | $1.17 | $1.73 | +12% | Neutral | |
| $0.8106 | $1.18 | $1.86 | +13% | Neutral | |
| $0.6855 | $1.05 | $1.74 | +1% | Neutral | |
| $0.9391 | $1.51 | $2.60 | +45% | Bullish | |
| $1.16 | $1.95 | $3.48 | +88% | Bullish | |
| $1.16 | $2.04 | $3.75 | +96% | Bullish | |
| $1.30 | $2.37 | $4.48 | +127% | Bullish | |
| $1.19 | $2.25 | $4.37 | +116% | Bullish | |
| $1.07 | $2.10 | $4.18 | +102% | Bullish | |
| $1.61 | $3.57 | $7.79 | +243% | Bullish | |
| $3.74 | $8.31 | $19.11 | +699% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.909 | $1.04 | $1.23 | +0.00% |
| September 2026 | $0.8163 | $0.9917 | $1.26 | -4.65% |
| October 2026 | $0.8673 | $1.07 | $1.38 | +7.72% |
| November 2026 | $0.877 | $1.09 | $1.43 | +2.26% |
| December 2026 | $0.8427 | $1.06 | $1.41 | -2.91% |
Click any year to see its month-by-month ABVC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ABVC could reach as high as $1.41, with a base case around $1.04 and support toward $0.909 — roughly 0% from $1.04. A consolidation phase looks the most probable path here.
Expect ABVC to range from $0.8518 to $1.73 through 2027. The $1.17 average target implies a +12% move from current prices. That is up +12% on the projected 2026 average. Price action looks broadly range-bound.
The ABVC price prediction for 2028 points to an average of $1.18 (low $0.8106, high $1.86) — a potential gain of +13% on today's $1.04. A consolidation phase looks the most probable path here.
In 2029, ABVC is projected to trade between $0.6855 and $1.74, averaging $1.05 — a potential gain of +1% from today's $1.04. That is -11% versus the projected 2028 average. Price action looks broadly range-bound.
ABVC BioPharma, Inc.'s 2030 outlook centres on $1.51, within a $0.9391 to $2.60 range. That is up +44% on the projected 2029 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, ABVC could reach as high as $3.48, with a base case around $1.95 and support toward $1.16 — roughly +88% from $1.04. Momentum favours further upside here.
Expect ABVC to range from $1.16 to $3.75 through 2032. The $2.04 average target implies a +96% move from current prices. That is up +4% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The ABVC price prediction for 2033 points to an average of $2.37 (low $1.30, high $4.48) — a potential gain of +127% on today's $1.04. Momentum favours further upside here.
In 2034, ABVC is projected to trade between $1.19 and $4.37, averaging $2.25 — a potential gain of +116% from today's $1.04. That is -5% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
ABVC BioPharma, Inc.'s 2035 outlook centres on $2.10, within a $1.07 to $4.18 range. That is -6% versus the projected 2034 average. That marks a +102% change versus current levels. Momentum favours further upside here.
By 2040, ABVC could reach as high as $7.79, with a base case around $3.57 and support toward $1.61 — roughly +243% from $1.04. Buyers look set to stay in control over this stretch.
Expect ABVC to range from $3.74 to $19.11 through 2050. The $8.31 average target implies a +699% move from current prices. That is up +133% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ABVC today (≈ 961.538462 ABVC) could be worth
$7,989
+$6,989 (+699%) by 2050 · US Dollar
Based on the average projected ABVC price of $8.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABVCwould be worth at today's price.
$1,000 invested in ABVC on Jul 31, 2025 (≈ 416.66665 ABVC) would be worth
$433.33
-$566.67 (-56.7%) today · 0.43× · US Dollar
Based on a ABVC entry price of $2.4 vs. today's $1.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.15 | $904.35 | -9.6% |
| 1 month ago | $1.77 | $587.57 | -41.2% |
| 3 months ago | $1.03 | $1,009.71 | +1.0% |
| 6 months ago | $1.89 | $550.26 | -45.0% |
| 1 year ago | $2.4 | $433.33 | -56.7% |
| All time (5.0y) ago | $31.75 | $32.76 | -96.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABVC forecast.
Our base-case forecast reaches $2.10 around 2033.
Implied market cap at $2.10: $54.6M
Over the multi-year horizon, the outlook shifts to a BULLISH stance from 2030 onward. The 2030 forecast shows an average price of $1.38 with a max of $2.40 and a min of $0.8568, yielding a 35.6 ROI and a bullish sentiment. The sequence continues with 2031 at an average of $1.75 and 71.1 ROI, 2032 at $1.83 (79.6 ROI), 2033 at $2.17 (113 ROI), 2034 at $1.98 (93.7 ROI), and 2035 at $1.80 (76.9 ROI), all carrying a bullish sentiment.
By 2040 the forecast rises to an average of $3.01 with a max of $6.61 and a 195.3 ROI, and by 2050 the average is $6.98 with a max of $16.06 and a 584.8 ROI, continuing the bullish trend. These are estimates, not guarantees, and reflect potential upside along with the inherent uncertainty and risk in future price movements.
Tap a question to reveal the answer.
2030 forecast: min $0.8568, avg $1.38, max $2.40; ROI 35.6; sentiment BULLISH.
Forecasts show neutral to bullish momentum from 2026 through 2029, turning bullish from 2030 onward with higher expected averages (2030 $1.38, 2031 $1.75, 2032 $1.83, 2033 $2.17) and strong 2040 ($3.01) and 2050 ($6.98) outlooks, but outcomes are not guaranteed and risk exists (e.g., 2029 ROI -6.2).
Yes, the 2050 forecast lists a max of $16.06 with an average of $6.98 and ROI of 584.8, indicating potential upside but not a guarantee.
Current price is $1.02 and market cap is $26.52M.
The near-term picture is Bearish with RSI(14) at 30, SMA50 at $1.35, SMA200 at $1.81, support at $1.02, resistance at $2.02, and a 30-day range from $0.6902 to $1.51 with volatility around 100%.
ABVC BioPharma, Inc. Community Discussion
0Share your ABVC BioPharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.